Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Rating of “Hold” from Brokerages

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have received a consensus recommendation of “Hold” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $29.6667.

UPB has been the topic of a number of analyst reports. Wall Street Zen cut Upstream Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Mizuho decreased their price target on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. HC Wainwright started coverage on Upstream Bio in a report on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price objective for the company. Truist Financial cut their price objective on Upstream Bio to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Finally, Weiss Ratings upgraded Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th.

Upstream Bio Trading Down 5.2%

Upstream Bio stock opened at $6.61 on Tuesday. The firm has a market capitalization of $362.04 million, a PE ratio of -2.28 and a beta of 1.26. Upstream Bio has a 12-month low of $5.85 and a 12-month high of $33.68. The firm has a 50-day moving average price of $6.88 and a 200-day moving average price of $8.74.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The company had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. As a group, sell-side analysts predict that Upstream Bio will post -2.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Torren Management LLC purchased a new position in Upstream Bio in the 4th quarter worth about $30,000. Empowered Funds LLC purchased a new stake in Upstream Bio in the 4th quarter valued at about $45,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Upstream Bio in the 4th quarter valued at about $71,000. Russell Investments Group Ltd. grew its stake in Upstream Bio by 1,963.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after acquiring an additional 2,887 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Upstream Bio by 229.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after acquiring an additional 2,158 shares in the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.